93 related articles for article (PubMed ID: 10549093)
1. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
Lutz MP; Königer M; Muche R; Ellenrieder V; Steinkamp M; Adler G; Gress TM
Z Gastroenterol; 1999 Oct; 37(10):993-7. PubMed ID: 10549093
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Kaubisch A; Kaleya R; Haynes H; Rozenblit A; Wadler S
Cancer Chemother Pharmacol; 2004 Apr; 53(4):337-40. PubMed ID: 14704829
[TBL] [Abstract][Full Text] [Related]
4. 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study.
Nose H; Okada S; Okusaka T; Furuse J; Yoshino M; Ogoshi K; Kato T; Miyaji M; Hoshino M; Ariyama J; Suyama M; Karasawa E; Yoshimori M
Hepatogastroenterology; 1999; 46(30):3244-8. PubMed ID: 10626195
[TBL] [Abstract][Full Text] [Related]
5. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma.
Ishii H; Okada S; Tokuuye K; Nose H; Okusaka T; Yoshimori M; Nagahama H; Sumi M; Kagami Y; Ikeda H
Cancer; 1997 Apr; 79(8):1516-20. PubMed ID: 9118032
[TBL] [Abstract][Full Text] [Related]
6. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
9. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
[TBL] [Abstract][Full Text] [Related]
10. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas.
Zimmermann FB; Jeremic B; Lersch C; Geinitz H; Hennig M; Molls M
Hepatogastroenterology; 2005; 52(61):246-50. PubMed ID: 15783041
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Tokuuye K
Oncology; 2004; 67(3-4):215-21. PubMed ID: 15557781
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of advanced pancreatic cancer with 5-fluorouracil, doxorubicin and high-dose methotrexate].
Scheithauer W; Ludwig H; Zielinski C; Funovics J; Knoflach P; Müller C; Grabner G
Leber Magen Darm; 1988 Jun; 18(3):149-55. PubMed ID: 3043129
[TBL] [Abstract][Full Text] [Related]
16. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
[TBL] [Abstract][Full Text] [Related]
17. [The role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer].
Wang CF; Zhao P; Shan Y; Zhao DB; Tian YT; Bai XF; Sun YM; Che X; Qu H; Xie YB
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):706-8. PubMed ID: 21122389
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Nicolson M; Webb A; Cunningham D; Norman A; O'Brien M; Hill A; Hickish T
Ann Oncol; 1995 Oct; 6(8):801-4. PubMed ID: 8589018
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study.
Kurtz JE; Kohser F; Négrier S; Trillet-Lenoir V; Walter S; Limacher JM; Untereiner M; Kayitalire L; Jaeck D; Dufour P
Hepatogastroenterology; 2000; 47(35):1450-3. PubMed ID: 11100374
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma.
Ulrich-Pur H; Kornek GV; Raderer M; Haider K; Kwasny W; Depisch D; Greul R; Schneeweiss B; Krauss G; Funovics J; Scheithauer W
Cancer; 2000 Jun; 88(11):2505-11. PubMed ID: 10861426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
